ID   SRC_RAT                 Reviewed;         536 AA.
AC   Q9WUD9; G3V776; Q45QJ2; Q9JJ10;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2013, sequence version 4.
DT   02-OCT-2024, entry version 214.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase Src;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:26026271, ECO:0000269|PubMed:28220894, ECO:0000269|PubMed:8849729};
DE   AltName: Full=Proto-oncogene c-Src;
DE   AltName: Full=pp60c-src;
DE            Short=p60-Src;
GN   Name=Src;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RA   Stockand J.D., Al-Khalili O., Spier B.J., Eaton D.C.;
RT   "Rattus norvegicus proto-oncogene encoding tyrosine-protein kinase pp60-c-
RT   src.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND INDUCTION.
RC   STRAIN=Wistar; TISSUE=Temporal cortex;
RX   PubMed=11249956; DOI=10.1016/s0028-3908(00)00185-4;
RA   Linden A., Storvik M., Lakso M., Haapasalo A., Lee D., Witkin J.M., Sei Y.,
RA   Castren E., Wong G.;
RT   "Increased expression of neuronal Src and tyrosine phosphorylation of NMDA
RT   receptors in rat brain after systemic treatment with MK-801.";
RL   Neuropharmacology 40:469-481(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-529 (ISOFORM 1).
RC   STRAIN=SHR, and Wistar Kyoto;
RA   Jackson E.K., Zhu C.;
RT   "Genetic similarity between spontaneously hypertensive rats and Wistar-
RT   Kyoto rats in the coding regions of signal transduction proteins.";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH PTK2B/PYK2, AND
RP   PHOSPHORYLATION AT TYR-419.
RX   PubMed=8849729; DOI=10.1038/383547a0;
RA   Dikic I., Tokiwa G., Lev S., Courtneidge S.A., Schlessinger J.;
RT   "A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP
RT   kinase activation.";
RL   Nature 383:547-550(1996).
RN   [7]
RP   INTERACTION WITH ARRB1.
RX   PubMed=10995467; DOI=10.1073/pnas.190276697;
RA   DeFea K.A., Vaughn Z.D., O'Bryan E.M., Nishijima D., Dery O., Bunnett N.W.;
RT   "The proliferative and antiapoptotic effects of substance P are facilitated
RT   by formation of a beta -arrestin-dependent scaffolding complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:11086-11091(2000).
RN   [8]
RP   INTERACTION WITH DDR2.
RX   PubMed=11884411; DOI=10.1074/jbc.m201078200;
RA   Ikeda K., Wang L.H., Torres R., Zhao H., Olaso E., Eng F.J., Labrador P.,
RA   Klein R., Lovett D., Yancopoulos G.D., Friedman S.L., Lin H.C.;
RT   "Discoidin domain receptor 2 interacts with Src and Shc following its
RT   activation by type I collagen.";
RL   J. Biol. Chem. 277:19206-19212(2002).
RN   [9]
RP   INTERACTION WITH DAB2.
RX   PubMed=12473651; DOI=10.1074/jbc.m210628200;
RA   Zhou J., Scholes J., Hsieh J.T.;
RT   "Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in
RT   normal prostatic epithelium and cancer.";
RL   J. Biol. Chem. 278:6936-6941(2003).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH DDR2.
RX   PubMed=16186108; DOI=10.1074/jbc.m506921200;
RA   Yang K., Kim J.H., Kim H.J., Park I.S., Kim I.Y., Yang B.S.;
RT   "Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src
RT   stimulates intramolecular autophosphorylation and Shc signaling complex
RT   formation.";
RL   J. Biol. Chem. 280:39058-39066(2005).
RN   [11]
RP   INTERACTION WITH CEACAM1.
RX   PubMed=19948503; DOI=10.1083/jcb.200904150;
RA   Mueller M.M., Klaile E., Vorontsova O., Singer B.B., Obrink B.;
RT   "Homophilic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and
RT   recruitment of SHP-2 and c-Src.";
RL   J. Cell Biol. 187:569-581(2009).
RN   [12]
RP   PHOSPHORYLATION AT TYR-530, AND DEPHOSPHORYLATION AT TYR-530 BY PTPRJ.
RX   PubMed=15735685; DOI=10.1038/sj.onc.1208510;
RA   Pera I.L., Iuliano R., Florio T., Susini C., Trapasso F., Santoro M.,
RA   Chiariotti L., Schettini G., Viglietto G., Fusco A.;
RT   "The rat tyrosine phosphatase eta increases cell adhesion by activating c-
RT   Src through dephosphorylation of its inhibitory phosphotyrosine residue.";
RL   Oncogene 24:3187-3195(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [14]
RP   FUNCTION (ISOFORMS 1; 2 AND 3), CATALYTIC ACTIVITY (ISOFORMS 1; 2 AND 3),
RP   ALTERNATIVE SPLICING, AND PHOSPHORYLATION AT TYR-419 AND TYR-530.
RX   PubMed=26026271; DOI=10.1016/j.febslet.2015.05.033;
RA   Keenan S., Lewis P.A., Wetherill S.J., Dunning C.J., Evans G.J.;
RT   "The N2-Src neuronal splice variant of C-Src has altered SH3 domain ligand
RT   specificity and a higher constitutive activity than N1-Src.";
RL   FEBS Lett. 589:1995-2000(2015).
RN   [15]
RP   FUNCTION (ISOFORMS 2 AND 3), AND CATALYTIC ACTIVITY.
RX   PubMed=28220894; DOI=10.1038/srep43106;
RA   Keenan S., Wetherill S.J., Ugbode C.I., Chawla S., Brackenbury W.J.,
RA   Evans G.J.;
RT   "Inhibition of N1-Src kinase by a specific SH3 peptide ligand reveals a
RT   role for N1-Src in neurite elongation by L1-CAM.";
RL   Sci. Rep. 7:43106-43106(2017).
CC   -!- FUNCTION: Non-receptor protein tyrosine kinase which is activated
CC       following engagement of many different classes of cellular receptors
CC       including immune response receptors, integrins and other adhesion
CC       receptors, receptor protein tyrosine kinases, G protein-coupled
CC       receptors as well as cytokine receptors. Participates in signaling
CC       pathways that control a diverse spectrum of biological activities
CC       including gene transcription, immune response, cell adhesion, cell
CC       cycle progression, apoptosis, migration, and transformation. Due to
CC       functional redundancy between members of the SRC kinase family,
CC       identification of the specific role of each SRC kinase is very
CC       difficult. SRC appears to be one of the primary kinases activated
CC       following engagement of receptors and plays a role in the activation of
CC       other protein tyrosine kinase (PTK) families. Receptor clustering or
CC       dimerization leads to recruitment of SRC to the receptor complexes
CC       where it phosphorylates the tyrosine residues within the receptor
CC       cytoplasmic domains. Plays an important role in the regulation of
CC       cytoskeletal organization through phosphorylation of specific
CC       substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2
CC       domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal
CC       reorganization is also controlled through the phosphorylation of
CC       cortactin (CTTN) (Probable). When cells adhere via focal adhesions to
CC       the extracellular matrix, signals are transmitted by integrins into the
CC       cell resulting in tyrosine phosphorylation of a number of focal
CC       adhesion proteins, including PTK2/FAK1 and paxillin (PXN) (By
CC       similarity). In addition to phosphorylating focal adhesion proteins,
CC       SRC is also active at the sites of cell-cell contact adherens junctions
CC       and phosphorylates substrates such as beta-catenin (CTNNB1), delta-
CC       catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell
CC       junction, the gap junction, is also a target for SRC, which
CC       phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of
CC       pre-mRNA-processing and phosphorylates RNA-binding proteins such as
CC       KHDRBS1 (Probable). Phosphorylates PKP3 at 'Tyr-195' in response to
CC       reactive oxygen species, which may cause the release of PKP3 from
CC       desmosome cell junctions into the cytoplasm (By similarity). Also plays
CC       a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and
CC       STAT3, leading to increased DNA binding activity of these transcription
CC       factors (By similarity). Involved in the RAS pathway through
CC       phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated
CC       calcium-activated chloride channel activation (By similarity). Required
CC       for epidermal growth factor receptor (EGFR) internalization through
CC       phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-
CC       1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization
CC       through phosphorylation and activation of GRK2, leading to beta-
CC       arrestin phosphorylation and internalization. Has a critical role in
CC       the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase
CC       cascade by epidermal growth factor (Probable). Might be involved not
CC       only in mediating the transduction of mitogenic signals at the level of
CC       the plasma membrane but also in controlling progression through the
CC       cell cycle via interaction with regulatory proteins in the nucleus.
CC       Plays an important role in osteoclastic bone resorption in conjunction
CC       with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC
CC       kinase activity are necessary for this function. Recruited to activated
CC       integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn
CC       induces the activation and recruitment of phosphatidylinositol 3-kinase
CC       to the cell membrane in a signaling pathway that is critical for
CC       osteoclast function. Promotes energy production in osteoclasts by
CC       activating mitochondrial cytochrome C oxidase (By similarity).
CC       Phosphorylates DDR2 on tyrosine residues, thereby promoting its
CC       subsequent autophosphorylation (PubMed:16186108). Phosphorylates RUNX3
CC       and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-738'.
CC       Enhances RIGI-elicited antiviral signaling. Phosphorylates PDPK1 at
CC       'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-226'.
CC       Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at
CC       'Tyr-341' activates CBLC E3 activity. Phosphorylates synaptic vesicle
CC       protein synaptophysin (SYP) (PubMed:26026271). Involved in anchorage-
CC       independent cell growth (By similarity). Required for podosome
CC       formation (By similarity). Mediates IL6 signaling by activating YAP1-
CC       NOTCH pathway to induce inflammation-induced epithelial regeneration
CC       (By similarity). Phosphorylates OTUB1, promoting deubiquitination of
CC       RPTOR (By similarity). {ECO:0000250|UniProtKB:P05480,
CC       ECO:0000250|UniProtKB:P12931, ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:26026271, ECO:0000305}.
CC   -!- FUNCTION: [Isoform 1]: Non-receptor protein tyrosine kinase which
CC       phosphorylates synaptophysin with high affinity.
CC       {ECO:0000269|PubMed:26026271}.
CC   -!- FUNCTION: [Isoform 2]: Non-receptor protein tyrosine kinase which shows
CC       higher basal kinase activity than isoform 1, possibly due to weakened
CC       intramolecular interactions which enhance autophosphorylation of Tyr-
CC       419 and subsequent activation (PubMed:26026271). The SH3 domain shows
CC       reduced affinity with the linker sequence between the SH2 and kinase
CC       domains which may account for the increased basal activity
CC       (PubMed:26026271). Displays altered substrate specificity compared to
CC       isoform 1, showing weak affinity for synaptophysin and for peptide
CC       substrates containing class I or class II SH3 domain-binding motifs
CC       (PubMed:26026271). Plays a role in L1CAM-mediated neurite elongation,
CC       possibly by acting downstream of L1CAM to drive cytoskeletal
CC       rearrangements involved in neurite outgrowth (PubMed:28220894).
CC       {ECO:0000269|PubMed:26026271, ECO:0000269|PubMed:28220894}.
CC   -!- FUNCTION: [Isoform 3]: Non-receptor protein tyrosine kinase which shows
CC       higher basal kinase activity than isoform 1, possibly due to weakened
CC       intramolecular interactions which enhance autophosphorylation of Tyr-
CC       419 and subsequent activation (PubMed:26026271). The SH3 domain shows
CC       reduced affinity with the linker sequence between the SH2 and kinase
CC       domains which may account for the increased basal activity
CC       (PubMed:26026271). Displays altered substrate specificity compared to
CC       isoform 1, showing weak affinity for synaptophysin and for peptide
CC       substrates containing class I or class II SH3 domain-binding motifs
CC       (PubMed:26026271). Plays a role in neurite elongation
CC       (PubMed:28220894). {ECO:0000269|PubMed:26026271,
CC       ECO:0000269|PubMed:28220894}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:8849729};
CC   -!- CATALYTIC ACTIVITY: [Isoform 1]:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000269|PubMed:26026271, ECO:0000269|PubMed:28220894};
CC   -!- CATALYTIC ACTIVITY: [Isoform 2]:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000269|PubMed:26026271, ECO:0000269|PubMed:28220894};
CC   -!- CATALYTIC ACTIVITY: [Isoform 3]:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000269|PubMed:26026271};
CC   -!- ACTIVITY REGULATION: Phosphorylation by CSK at Tyr-530 inhibits kinase
CC       activity. Inhibitory phosphorylation at Tyr-530 is enhanced by heme.
CC       Further phosphorylation by CDK1 partially reactivates CSK-inactivated
CC       SRC and facilitates complete reactivation by protein tyrosine
CC       phosphatase PTPRC. Integrin engagement stimulates kinase activity.
CC       Phosphorylation by PTK2/FAK1 enhances kinase activity. Butein and
CC       pseudosubstrate-based peptide inhibitors like CIYKYYF act as inhibitors
CC       (By similarity). Phosphorylation at Tyr-419 increases kinase activity.
CC       {ECO:0000250, ECO:0000269|PubMed:8849729}.
CC   -!- SUBUNIT: Part of a complex comprised of PTPRA, BCAR1, BCAR3 (via SH2
CC       domain) and SRC; the formation of the complex is dependent on integrin
CC       mediated-tyrosine phosphorylation of PTPRA (By similarity). Interacts
CC       with DDEF1/ASAP1; via the SH3 domain (By similarity). Interacts with
CC       CCPG1 (By similarity). Identified in a complex containing FGFR4, NCAM1,
CC       CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN (By similarity). Interacts
CC       with ERBB2, STAT1 and PNN (By similarity). Interacts with CDCP1,
CC       TGFB1I1 and TOM1L2 (By similarity). Interacts with the cytoplasmic
CC       domain of MUC1, phosphorylates it and increases binding of MUC1 with
CC       beta-catenin (By similarity). Interacts with RALGPS1; via the SH3
CC       domain (By similarity). Interacts with CAV2 (tyrosine phosphorylated
CC       form) (By similarity). Interacts (via the SH3 domain and the protein
CC       kinase domain) with ARRB1; the interaction is independent of the
CC       phosphorylation state of SRC C-terminus (PubMed:10995467). Interacts
CC       with ARRB1 and ARRB2 (By similarity) (PubMed:10995467). Interacts with
CC       SRCIN1 (By similarity). Interacts with NDFIP2 and more weakly with
CC       NDFIP1 (By similarity). Interacts with PIK3CA and/or PIK3C2B, PTK2/FAK1
CC       and ESR1 (dimethylated on arginine) (PubMed:8849729). Interacts with
CC       FASLG (By similarity). Interacts (via SH2 domain) with the 'Tyr-402'
CC       phosphorylated form of PTK2B/PYK2 (PubMed:8849729). Interacts (via SH2
CC       domain) with FLT3 (tyrosine phosphorylated) (By similarity). Interacts
CC       (via SH2 and SH3 domain) with TNK2 (By similarity). Interacts (via
CC       protein kinase domain) with the tyrosine phosphorylated form of RUNX3
CC       (via runt domain) (By similarity). Interacts with TRAF3 (via RING-type
CC       zinc finger domain) (By similarity). Interacts with RIGI, MAVS and TBK1
CC       (By similarity). Interacts (via SH2 domain) with RACK1; the interaction
CC       is enhanced by tyrosine phosphorylation of RACK1 and inhibits SRC
CC       activity (By similarity). Interacts with EPHB1; activates the MAPK/ERK
CC       cascade to regulate cell migration (By similarity). Interacts with
CC       FCAMR (By similarity). Interacts with PDGFRA (tyrosine phosphorylated)
CC       (By similarity). Interacts with CSF1R (By similarity). Interacts with
CC       DDR1 (By similarity). Interacts (via SH2 domain) with the 'Tyr-9'
CC       phosphorylated form of PDPK1 (By similarity). Interacts with AMOTL2;
CC       this interaction promotes the translocation of phosphorylated SRC to
CC       peripheral cell-matrix adhesion sites (By similarity). Interacts with
CC       DDR2 and DAB2 (PubMed:11884411, PubMed:12473651, PubMed:16186108).
CC       Interacts with TRAP1 (By similarity). Interacts with CBLC; the
CC       interaction is enhanced when SRC is phosphorylated at Tyr-419 (By
CC       similarity). Interacts with ARHGEF5 (By similarity). Interacts (via
CC       cytoplasmic domain) with CEACAM1 (via SH2 domain); this interaction is
CC       regulated by trans-homophilic cell adhesion (PubMed:19948503).
CC       Interacts with MPP2 (By similarity). Interacts with PRR7 (By
CC       similarity). Interacts (via kinase domain and to a lesser extent the
CC       SH2 domain) directly with PDLIM4; this interaction results in PTPN13-
CC       mediated dephosphorylation of this protein leading to its inactivation
CC       (By similarity). Interacts with P85 (PIK3R1 or PIK3R2) (By similarity).
CC       Interacts with HNRNPA2B1 (By similarity). Interacts with IL6ST/gp130
CC       (By similarity). Interacts (via SH3 domain) with PELP1 in the presence
CC       of 17-beta-estradiol (By similarity). Interacts with AMBRA1 (By
CC       similarity). {ECO:0000250|UniProtKB:P05480,
CC       ECO:0000250|UniProtKB:P12931, ECO:0000269|PubMed:10995467,
CC       ECO:0000269|PubMed:11884411, ECO:0000269|PubMed:12473651,
CC       ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:19948503,
CC       ECO:0000269|PubMed:8849729}.
CC   -!- INTERACTION:
CC       Q9WUD9; P22002: Cacna1c; NbExp=4; IntAct=EBI-7784541, EBI-1185084;
CC       Q9WUD9; P28648: Cd63; NbExp=2; IntAct=EBI-7784541, EBI-7784314;
CC       Q9WUD9; O08617: Ptprr; NbExp=2; IntAct=EBI-7784541, EBI-8584374;
CC       Q9WUD9; P18031: PTPN1; Xeno; NbExp=2; IntAct=EBI-7784541, EBI-968788;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P05480};
CC       Lipid-anchor {ECO:0000250|UniProtKB:P05480}. Mitochondrion inner
CC       membrane {ECO:0000250|UniProtKB:P05480}. Nucleus
CC       {ECO:0000250|UniProtKB:P05480}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:P05480}. Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:P12931}. Cell junction, focal adhesion
CC       {ECO:0000250|UniProtKB:P05480}. Note=Localizes to focal adhesion sites
CC       following integrin engagement. Localization to focal adhesion sites
CC       requires myristoylation and the SH3 domain (By similarity). Colocalizes
CC       with PDLIM4 at the perinuclear region, but not at focal adhesions.
CC       {ECO:0000250|UniProtKB:P05480, ECO:0000250|UniProtKB:P12931}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=c-Src {ECO:0000303|PubMed:26026271};
CC         IsoId=Q9WUD9-1; Sequence=Displayed;
CC       Name=2; Synonyms=Neuronal Src, N1-Src {ECO:0000303|PubMed:26026271};
CC         IsoId=Q9WUD9-2; Sequence=VSP_053395;
CC       Name=3; Synonyms=N2-Src {ECO:0000303|PubMed:26026271};
CC         IsoId=Q9WUD9-3; Sequence=VSP_061495;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Expressed at very low levels in the
CC       forebrain. {ECO:0000269|PubMed:11249956}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in the brain with highest
CC       expression in the pyramidal layers of the hippocampus and the granular
CC       layer of the dentate gyrus and moderate expression in cortical regions,
CC       with higher levels in the superficial layers than in the deep layers.
CC       May be neuron-specific. {ECO:0000269|PubMed:11249956}.
CC   -!- INDUCTION: [Isoform 2]: Up-regulated by MK-801, an uncompetitive N-
CC       methyl-d-aspartate (NMDA) receptor antagonist, mostly in the
CC       superficial layers of the parietal, temporal, occipital and frontal
CC       cortices. {ECO:0000269|PubMed:11249956}.
CC   -!- PTM: Myristoylated at Gly-2, and this is essential for targeting to
CC       membranes. {ECO:0000250}.
CC   -!- PTM: Dephosphorylated at Tyr-530 by PTPRJ. Phosphorylated on Tyr-530 by
CC       c-Src kinase (CSK). The phosphorylated form is termed pp60c-src (By
CC       similarity). Dephosphorylated by PTPRJ at Tyr-419. Normally maintained
CC       in an inactive conformation with the SH2 domain engaged with Tyr-530,
CC       the SH3 domain engaged with the SH2-kinase linker, and Tyr-419
CC       dephosphorylated. Dephosphorylation of Tyr-530 as a result of protein
CC       tyrosine phosphatase (PTP) action disrupts the intramolecular
CC       interaction between the SH2 domain and Tyr-530, Tyr-419 can then become
CC       autophosphorylated, resulting in SRX activation. Phosphorylation of
CC       Tyr-530 by CSK allows this interaction to reform, resulting in SRC
CC       inactivation. CDK5-mediated phosphorylation at Ser-75 targets SRC to
CC       ubiquitin-dependent degradation and thus leads to cytoskeletal
CC       reorganization. Phosphorylated by PTK2/FAK1; this enhances kinase
CC       activity (By similarity). Phosphorylated by PTK2B/PYK2; this enhances
CC       kinase activity. Upon activation of IL6ST by IL6, Tyr-419 is
CC       phosphorylated and Tyr-530 dephosphorylated (By similarity).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P12931,
CC       ECO:0000269|PubMed:15735685, ECO:0000269|PubMed:8849729}.
CC   -!- PTM: [Isoform 1]: Displays reduced levels of autophosphorylation at
CC       Tyr-419 compared to isoforms 2 and 3. {ECO:0000269|PubMed:26026271}.
CC   -!- PTM: [Isoform 2]: Displays enhanced levels of autophosphorylation at
CC       Tyr-419 compared to isoform 1. {ECO:0000269|PubMed:26026271}.
CC   -!- PTM: [Isoform 3]: Displays enhanced levels of autophosphorylation at
CC       Tyr-419 compared to isoform 1 (PubMed:26026271). Shows reduced
CC       phosphorylation at Tyr-527 compared to isoforms 1 and 2
CC       (PubMed:26026271). {ECO:0000269|PubMed:26026271}.
CC   -!- PTM: S-nitrosylation is important for activation of its kinase
CC       activity. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated in response to CDK5-mediated phosphorylation.
CC       Ubiquitination mediated by CBLC requires SRC autophosphorylation at
CC       Tyr-419 and may lead to lysosomal degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF130457; AAD24180.1; -; mRNA.
DR   EMBL; AF157016; AAF80335.1; -; mRNA.
DR   EMBL; AABR06027223; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH474005; EDL96675.1; -; Genomic_DNA.
DR   EMBL; CH474005; EDL96676.1; -; Genomic_DNA.
DR   EMBL; CH474005; EDL96677.1; -; Genomic_DNA.
DR   EMBL; CH474005; EDL96678.1; -; Genomic_DNA.
DR   EMBL; CH474005; EDL96679.1; -; Genomic_DNA.
DR   EMBL; DQ120509; AAZ23848.1; -; mRNA.
DR   EMBL; DQ120510; AAZ23849.1; -; mRNA.
DR   RefSeq; NP_114183.1; NM_031977.1. [Q9WUD9-2]
DR   RefSeq; XP_008760609.1; XM_008762387.2.
DR   RefSeq; XP_008760610.1; XM_008762388.2.
DR   RefSeq; XP_017447554.1; XM_017592065.1.
DR   RefSeq; XP_017447555.1; XM_017592066.1. [Q9WUD9-2]
DR   RefSeq; XP_017447556.1; XM_017592067.1.
DR   RefSeq; XP_017447557.1; XM_017592068.1. [Q9WUD9-2]
DR   RefSeq; XP_017447558.1; XM_017592069.1.
DR   RefSeq; XP_017447559.1; XM_017592070.1.
DR   RefSeq; XP_017447560.1; XM_017592071.1. [Q9WUD9-2]
DR   RefSeq; XP_017447561.1; XM_017592072.1.
DR   AlphaFoldDB; Q9WUD9; -.
DR   SMR; Q9WUD9; -.
DR   BioGRID; 249840; 18.
DR   CORUM; Q9WUD9; -.
DR   DIP; DIP-42731N; -.
DR   ELM; Q9WUD9; -.
DR   IntAct; Q9WUD9; 33.
DR   MINT; Q9WUD9; -.
DR   STRING; 10116.ENSRNOP00000071837; -.
DR   BindingDB; Q9WUD9; -.
DR   ChEMBL; CHEMBL3014; -.
DR   iPTMnet; Q9WUD9; -.
DR   PhosphoSitePlus; Q9WUD9; -.
DR   jPOST; Q9WUD9; -.
DR   PaxDb; 10116-ENSRNOP00000012739; -.
DR   PeptideAtlas; Q9WUD9; -.
DR   Ensembl; ENSRNOT00000012739.5; ENSRNOP00000012739.3; ENSRNOG00000009495.7. [Q9WUD9-2]
DR   Ensembl; ENSRNOT00000080516.2; ENSRNOP00000071837.2; ENSRNOG00000009495.7. [Q9WUD9-1]
DR   Ensembl; ENSRNOT00055046517; ENSRNOP00055038157; ENSRNOG00055026954. [Q9WUD9-1]
DR   Ensembl; ENSRNOT00060040642; ENSRNOP00060033591; ENSRNOG00060023461. [Q9WUD9-1]
DR   Ensembl; ENSRNOT00065047008; ENSRNOP00065038576; ENSRNOG00065027238. [Q9WUD9-1]
DR   GeneID; 83805; -.
DR   KEGG; rno:83805; -.
DR   UCSC; RGD:620795; rat. [Q9WUD9-1]
DR   AGR; RGD:620795; -.
DR   CTD; 6714; -.
DR   RGD; 620795; Src.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000158250; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; Q9WUD9; -.
DR   OMA; NYIAPVK; -.
DR   OrthoDB; 1614410at2759; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 5301.
DR   Reactome; R-RNO-1227986; Signaling by ERBB2.
DR   Reactome; R-RNO-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-RNO-1253288; Downregulation of ERBB4 signaling.
DR   Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-RNO-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-RNO-1433557; Signaling by SCF-KIT.
DR   Reactome; R-RNO-1433559; Regulation of KIT signaling.
DR   Reactome; R-RNO-177929; Signaling by EGFR.
DR   Reactome; R-RNO-180292; GAB1 signalosome.
DR   Reactome; R-RNO-186763; Downstream signal transduction.
DR   Reactome; R-RNO-191650; Regulation of gap junction activity.
DR   Reactome; R-RNO-2029481; FCGR activation.
DR   Reactome; R-RNO-210990; PECAM1 interactions.
DR   Reactome; R-RNO-354192; Integrin signaling.
DR   Reactome; R-RNO-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-RNO-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-RNO-389356; CD28 co-stimulation.
DR   Reactome; R-RNO-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-RNO-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-RNO-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-RNO-3928664; Ephrin signaling.
DR   Reactome; R-RNO-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-RNO-418592; ADP signalling through P2Y purinoceptor 1.
DR   Reactome; R-RNO-418594; G alpha (i) signalling events.
DR   Reactome; R-RNO-418885; DCC mediated attractive signaling.
DR   Reactome; R-RNO-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-RNO-437239; Recycling pathway of L1.
DR   Reactome; R-RNO-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-RNO-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-RNO-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-RNO-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-RNO-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-RNO-5673000; RAF activation.
DR   Reactome; R-RNO-5674135; MAP2K and MAPK activation.
DR   Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-RNO-69231; Cyclin D associated events in G1.
DR   Reactome; R-RNO-8853659; RET signaling.
DR   Reactome; R-RNO-8874081; MET activates PTK2 signaling.
DR   Reactome; R-RNO-8934903; Receptor Mediated Mitophagy.
DR   Reactome; R-RNO-8941858; Regulation of RUNX3 expression and activity.
DR   Reactome; R-RNO-9009391; Extra-nuclear estrogen signaling.
DR   Reactome; R-RNO-9603381; Activated NTRK3 signals through PI3K.
DR   PRO; PR:Q9WUD9; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Proteomes; UP000234681; Chromosome 3.
DR   Bgee; ENSRNOG00000009495; Expressed in frontal cortex and 19 other cell types or tissues.
DR   GO; GO:0005884; C:actin filament; ISO:RGD.
DR   GO; GO:0005901; C:caveola; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:1902737; C:dendritic filopodium; IDA:RGD.
DR   GO; GO:0044294; C:dendritic growth cone; IDA:RGD.
DR   GO; GO:0005925; C:focal adhesion; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005770; C:late endosome; ISO:RGD.
DR   GO; GO:0005764; C:lysosome; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0002102; C:podosome; ISO:RGD.
DR   GO; GO:0099091; C:postsynaptic specialization, intracellular component; IDA:SynGO.
DR   GO; GO:0032587; C:ruffle membrane; ISO:RGD.
DR   GO; GO:0097060; C:synaptic membrane; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0070700; F:BMP receptor binding; ISO:RGD.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:RGD.
DR   GO; GO:0071253; F:connexin binding; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; IPI:RGD.
DR   GO; GO:0046875; F:ephrin receptor binding; ISO:RGD.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0005158; F:insulin receptor binding; IPI:RGD.
DR   GO; GO:0005178; F:integrin binding; ISO:RGD.
DR   GO; GO:0016301; F:kinase activity; ISO:RGD.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; ISO:RGD.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:RGD.
DR   GO; GO:0016004; F:phospholipase activator activity; ISO:RGD.
DR   GO; GO:0043274; F:phospholipase binding; ISO:RGD.
DR   GO; GO:0051219; F:phosphoprotein binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:RGD.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; ISO:RGD.
DR   GO; GO:0042169; F:SH2 domain binding; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:RGD.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:RGD.
DR   GO; GO:0034332; P:adherens junction organization; IEP:RGD.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; ISO:RGD.
DR   GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISO:RGD.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; ISO:RGD.
DR   GO; GO:0098609; P:cell-cell adhesion; IEP:RGD.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEP:RGD.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEP:RGD.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; ISO:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; ISO:RGD.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEP:RGD.
DR   GO; GO:0071393; P:cellular response to progesterone stimulus; IMP:BHF-UCL.
DR   GO; GO:1990646; P:cellular response to prolactin; IEP:RGD.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; ISS:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; ISO:RGD.
DR   GO; GO:0071897; P:DNA biosynthetic process; IMP:RGD.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IEP:RGD.
DR   GO; GO:0048041; P:focal adhesion assembly; ISO:RGD.
DR   GO; GO:0030900; P:forebrain development; ISO:RGD.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0060576; P:intestinal epithelial cell development; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:RGD.
DR   GO; GO:0007611; P:learning or memory; IEP:RGD.
DR   GO; GO:0051450; P:myoblast proliferation; IEP:RGD.
DR   GO; GO:2000811; P:negative regulation of anoikis; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:RGD.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0035331; P:negative regulation of hippo signaling; ISO:RGD.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0051902; P:negative regulation of mitochondrial depolarization; ISO:RGD.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; ISO:RGD.
DR   GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; ISO:RGD.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:RGD.
DR   GO; GO:0042476; P:odontogenesis; ISO:RGD.
DR   GO; GO:0048477; P:oogenesis; ISO:RGD.
DR   GO; GO:0036035; P:osteoclast development; ISO:RGD.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:CACAO.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:RGD.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IMP:RGD.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISO:RGD.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IMP:RGD.
DR   GO; GO:0035306; P:positive regulation of dephosphorylation; ISO:RGD.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; ISO:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:RGD.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISO:RGD.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IDA:RGD.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:RGD.
DR   GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; ISO:RGD.
DR   GO; GO:2000256; P:positive regulation of male germ cell proliferation; IMP:RGD.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISO:RGD.
DR   GO; GO:2000386; P:positive regulation of ovarian follicle development; IMP:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:RGD.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB.
DR   GO; GO:2000588; P:positive regulation of platelet-derived growth factor receptor-beta signaling pathway; ISO:RGD.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; ISO:RGD.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; ISO:RGD.
DR   GO; GO:0010954; P:positive regulation of protein processing; ISO:RGD.
DR   GO; GO:0051222; P:positive regulation of protein transport; IMP:RGD.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IMP:RGD.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; ISO:RGD.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:RGD.
DR   GO; GO:1904263; P:positive regulation of TORC1 signaling; ISO:RGD.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0001545; P:primary ovarian follicle growth; IMP:RGD.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0031648; P:protein destabilization; ISO:RGD.
DR   GO; GO:2001286; P:regulation of caveolin-mediated endocytosis; ISO:RGD.
DR   GO; GO:0060491; P:regulation of cell projection assembly; ISO:RGD.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; ISO:RGD.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; ISO:RGD.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; ISO:RGD.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; ISO:RGD.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0034139; P:regulation of toll-like receptor 3 signaling pathway; ISO:RGD.
DR   GO; GO:0010447; P:response to acidic pH; IEP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0070542; P:response to fatty acid; IEP:RGD.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0070555; P:response to interleukin-1; ISO:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0051385; P:response to mineralocorticoid; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0014856; P:skeletal muscle cell proliferation; IEP:RGD.
DR   GO; GO:0007283; P:spermatogenesis; IEP:RGD.
DR   GO; GO:0043149; P:stress fiber assembly; ISO:RGD.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; ISO:RGD.
DR   GO; GO:0045056; P:transcytosis; IDA:RGD.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISO:RGD.
DR   GO; GO:0060065; P:uterus development; ISO:RGD.
DR   CDD; cd05071; PTKc_Src; 1.
DR   CDD; cd10365; SH2_Src_Src; 1.
DR   CDD; cd12008; SH3_Src; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR050198; Non-receptor_tyrosine_kinases.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   PANTHER; PTHR24418:SF53; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC; 1.
DR   PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell adhesion; Cell cycle;
KW   Cell junction; Cell membrane; Cytoplasm; Cytoskeleton; Immunity; Kinase;
KW   Lipoprotein; Membrane; Mitochondrion; Mitochondrion inner membrane;
KW   Myristate; Nucleotide-binding; Nucleus; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P12931"
FT   CHAIN           2..536
FT                   /note="Proto-oncogene tyrosine-protein kinase Src"
FT                   /id="PRO_0000088143"
FT   DOMAIN          84..145
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          151..248
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          270..523
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..49
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        389
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         276..284
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         298
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         75
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000250|UniProtKB:P12931"
FT   MOD_RES         187
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05480"
FT   MOD_RES         419
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:26026271"
FT   MOD_RES         419
FT                   /note="Phosphotyrosine; by FAK2"
FT                   /evidence="ECO:0000269|PubMed:8849729"
FT   MOD_RES         530
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000269|PubMed:26026271"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         117
FT                   /note="T -> TRKVDVR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11249956"
FT                   /id="VSP_053395"
FT   VAR_SEQ         117
FT                   /note="T -> TRKVDVSQTWFTFRWLQR (in isoform 3)"
FT                   /id="VSP_061495"
FT   CONFLICT        143
FT                   /note="S -> F (in Ref. 1; AAD24180 and 5; AAZ23849/
FT                   AAZ23848)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        381
FT                   /note="E -> D (in Ref. 1; AAD24180 and 5; AAZ23849/
FT                   AAZ23848)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        528
FT                   /note="P -> R (in Ref. 1; AAD24180 and 5; AAZ23849/
FT                   AAZ23848)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   536 AA;  59973 MW;  453D1E904EC660A3 CRC64;
     MGSNKSKPKD ASQRRRSLEP AENVHGAGGA FPASQTPSKP ASADGHRGPN AAFVPPAAAE
     PKLFGGFNSS DTVTSPQRAG PLAGGVTTFV ALYDYESRTE TDLSFKKGER LQIVNNTEGD
     WWLAHSLSTG QTGYIPSNYV APSDSIQAEE WYFGKITRRE SERLLLNAEN PRGTFLVRES
     ETTKGAYCLS VSDFDNAKGL NVKHYKIRKL DSGGFYITSR TQFNSLQQLV AYYSKHADGL
     CHRLTTVCPT SKPQTQGLAK DAWEIPRESL RLEVKLGQGC FGEVWMGTWN GTTRVAIKTL
     KPGTMSPEAF LQEAQVMKKL RHEKLVQLYA VVSEEPIYIV TEYMNKGSLL DFLKGETGKY
     LRLPQLVDMS AQIASGMAYV ERMNYVHRDL RAANILVGEN LVCKVADFGL ARLIEDNEYT
     ARQGAKFPIK WTAPEAALYG RFTIKSDVWS FGILLTELTT KGRVPYPGMV NREVLDQVER
     GYRMPCPPEC PESLHDLMCQ CWRKEPEERP TFEYLQAFLE DYFTSTEPQY QPGENL
//
